key: cord-0972812-1v8g7jtb
authors: Goh, Bak Leong; Shanmuganathan, Malini; Peariasamy, Kalaiarasu; Misnan, Nor Arisah; Chidambaram, Suresh Kumar; Wong, Eddie Fook Sem; Pathmanathan, Mohan Dass; Ang, Kim Liong; Wong, Hin Seng; Yeap, Lena Lay Ling
title: COVID‐19 death and kidney disease in a multiracial Asian country
date: 2022-05-07
journal: Nephrology (Carlton)
DOI: 10.1111/nep.14045
sha: fed9b1c4dcad64a3dced780d22fbd4b415916abc
doc_id: 972812
cord_uid: 1v8g7jtb

INTRODUCTION: COVID‐19 infection and kidney disease (KD) carry a considerable risk of mortality. Understanding predictors of death and KD may help improve management and patient outcome. METHODS: This is a prospective multicentre observational study conducted in a multiracial Asian country to identify predictors of death and acute kidney injury (AKI) in hospitalized COVID‐19 patients from January to June 2020. RESULTS: A total of 6078 patients were included in this study. Mean age was 37.3 (±16.8) years, 71% were male, 59.4% Malay, 6.7% Chinese, 2.3% Indian and 31.7% other ethnicities. AKI was seen in 3.5% of patients while 1.6% had pre‐existing chronic kidney disease (CKD). Overall case fatality rate (CFR) was 1.3%. Patients with KD (AKI and CKD) had CFR of 20%. Many factors were associated with increased risk of death and AKI. However, significant predictors of death after adjustment for covariates were age (>70 years), Chinese ethnicity, diabetes mellitus (DM) and KD. Adjusted predictors of AKI were age (>51 years), DM and severity at presentation. Chinese were 2.58 times more likely to die (p = .036) compared to Malay. Centre capacity to manage, ventilate and dialyze patients significantly influenced death. Among those with AKI, the most common symptoms were fever, cough, and dyspnea. They had lower absolute lymphocyte count, were more likely to be admitted to ICU, required more ventilation and longer hospitalization. CONCLUSION: Patient and centre factors influence death and AKI among COVID‐19 patients. This study also demonstrates death disparities across different racial groups and centre capacities in this multiracial Asian country.

As of 1st July 2021, 181 722 790 confirmed cases of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated coronavirus disease 2019 (COVID -19) have been reported globally, including 3 942 233 deaths. 1 Studies have highlighted various risk factors associated with death and kidney disease (KD) in COVID -19 patients. In the west, high incidences of COVID-19 infection and mortality were reported to affect various ethnic groups differently, especially among minorities. This was mainly attributed to the lack of access to healthcare facilities and socio-economic reasons. 2, 3 Studies have shown that Asian minorities have comparable case fatality rate (CFR) with white people while other ethnic minorities like Black and Latinos have higher CFR. 4 With an abundance of different racial groups within Asia, it is possible for each race to have different risk factors associated with COVID-19 mortality. Unfortunately, literature elaborating on the mortality of different races within Asia is scarce. This could be because most studies pool Asian races together instead of analysing them independently.

Malaysia is unique in this sense as our 32.75 million population consists of three major racial groups in Asia, namely the Malays (69.7%) from the Malay Archipelago, the Chinese (22.5%) from East Asia and the Indians (6.8%) from South Asia, the Kadazan, Iban and Dayak from Borneo. This study was conducted to identify patient factors, comorbidities and centre factors linked to COVID-19 deaths and acute kidney injury (AKI) in our unique multiracial Asian population.

This is a prospective multicentre observational study involving data from 18 hospitals in Malaysia designated to treat COVID-19. Patients aged 12 years and above, who were admitted from January to June 2020, following positive reverse transcription polymerase chain reaction (RT-PCR) test were included in this study. Patient demographics including gender, age, race, clinical data, laboratory data and outcome were collected until their day of discharge. This study was approved by the Medical Research and Ethics Committee (NMRR-21-59-57 908). whereas stage 3 onwards is of severe disease. 5 In order to ensure that death statistics in Malaysia is in accordance with WHO guidelines, accurate classification of COVID-19 death is crucial. Causality of death due to COVID-19 was ascertained based on Ministry of Health guidelines that was developed following discussions with infectious disease medical specialists, forensic medical specialists and the national committee of COVID-19 mortality review.

The criteria for the classification of "Death due to COVID-19" for hospitalized patients is as follows: 2. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days OR;

3. Urine output of <0.5 ml/kg/h for 6 h.

Development of de novo CKD is defined as kidney damage or an eGFR<60 ml/min/1.73 m 2 present on at least two occasions for >3 months. Progression of pre-existing CKD is defined as decline in eGFR >15% or a decrease in eGFR >5 ml/min/1.73 m 2 over 12 months.

Liver injury is defined as deranged liver enzymes with or without deranged international normalized ratio (INR) or bilirubin. Bacteraemia is defined as culture positive with or without raised white cell count (WCC), raised C-reactive protein (CRP), signs and symptoms of infection. Cardiac complication includes endocarditis, cardiac arrythmia, cardiac ischemia, congestive heart failure and cardiac arrest. Coagulopathy is defined as abnormality of the haemostasis compartments such as thrombocytopenia, abnormally high-prothrombin time (PT)/INR or activated partial thromboplastin time.

Mean and standard deviation (SD) was used to represent normally distributed continuous variables, while median and interquartile range (IQR) was used to represent non-normally distributed continuous variables. Categorical variables were expressed in frequency and percentage (%). Mortality rate was expressed using CFR, which is calculated by dividing the number of deaths due to COVID-19 in a group of testpositive individuals over the period of study duration by the total number of individuals in that group. This value is then multiplied by 100 to yield a percentage value. CFR eases comparison with other studies as it is commonly used to estimate the proportion of deaths among identified COVID-19 cases.

The main outcomes of interest are death and AKI. Unadjusted and adjusted odds ratio of death and AKI was determined using univariate and multivariate logistic analysis and expressed using odds ratio (OR) and 95% confidence interval (CI). Potential confounders include demographic data such as age, gender, race, comorbidities like (Table 1 ).

Presenting symptoms of patients with KD (CKD, AKI) were fever (8, 14) , 14 (10, 28) and 14 (9, 24) days among non-KD, CKD and AKI patients respectively. There were 1.3% non-KD patients, 39%

CKD patients and 44.3% AKI patients admitted in ICU. Mechanical ventilation was required by 0.5% non-KD patients, 32% CKD patients and 40.6% AKI patients ( Table 2 ).

Steroid treatment was given to 27 (0.5%) of non KD patients, 11 (11%) of CKD patients and 17 (8%) of AKI patients. Six hundred and ninety-seven (12%), 54 (54%) and 107 (50%) of patients were administered with antiviral medication within the non-KD, CKD and AKI groups respectively ( Table 2 ). Among patients with KD, the median proportion of those who required KRT was 8.9%. The provision of KRT between hospitals varied widely, with 18.58% as the upper limit of the interquartile range (Table 3 ).

Unadjusted risk factors for AKI were age, race, comorbidities such as hypertension, DM, obesity, chronic cardiac disease, chronic pulmonary disease and severity (stages) of COVID-19 infection upon presentation (Table 4 ). After adjusting for other confounders, age, DM and severity upon presentation were found to be significant predictors of AKI. Individuals who were older than 51 years had higher risk 

The overall CFR was 1.3%. Chinese patients had higher CFR compared to other races (Chinese 3.7%, Malay 1.3%, Indian 1.4% and other races 0.7%). CFR for those with KD was notably higher (20.2%).

Chinese patients with KD were more likely to die with CFR of 32.4%, followed by other races ( (Table 7) . This may lead to severe disease and even death. Micro and macrovascular complications associated with diabetes such as nephropathy and coronary artery disease could also influence the outcome of COVID-19 patients.

Mortality reporting in the top 10 countries with high COVID-19 case notification, surprisingly did not require race related information. 19 Nevertheless, racial differences have been reported as a contributing factor of death in the west. [2] [3] [4] 20 When this disease first emerged, focus was mostly on pulmonary manifestations as its mode of transmission was through the respiratory tract. However, symptoms related to other organ involvement begun to surface soon after. Extra-pulmonary involvement and its association with patient outcome has received much more scrutiny ever since. In our cohort, 3.5% of patients developed AKI. Some studies had higher prevalence of AKI while others were similar to ours.

With the clinical presentation of COVID-19 infection broadly variable, it is hardly surprising that AKI prevalence has such a wide range (5.1%-70.7%). 13 With about 10% of the world's population suffering from CKD, it has emerged as a huge public health concern. 6,28 If left unmonitored, this "silent killer" may lead to end stage KD, development of cardiovascular disease and even sudden death. 29 Many studies have demonstrated that pre-existing CKD was a significant contributing factor to severity (OR 3-3.3) and mortality (28%-41%) in COVID-19

patients. 9, 11, [30] [31] [32] this study, centre capacity to treat more patients and ability to provide more KRT were found to be associated with lower mortality. The reason for this is yet to be determined. However, there are some possible explanations. Lower risk of death in larger centres could be a reflection of the presence of better facilities and more experienced medical staff. Despite being statistically insignificant, our univariate analysis showed that centres with less ventilation capacity and centres with larger ventilation capacity had lower risk of death compared to centres with medium ventilation capacity. However, after adjusting for patient demographics, centres with medium and larger ventilation capacity had six times higher risk of death compared to centres with less ventilation capacity. This could be because centres with less ventilation capacity, manage fewer and less severe patients thus have lower risk of death. Further studies should be done to evaluate the association between centre ventilation capacity and mortality.

The strength of this study is that it involves big data from multiple centres in a multiracial country. The data contains a colossal of demographic and clinical information that is important, especially now as the pandemic has projected more questions than answers. Statistical analysis, particularly multivariate regression was more meaningful with the availability of this comprehensive data. This study however, has its limitations. As information was collected and submitted volun- 

COVID-19: unique public health issues facing black, Asian and minority ethnic communities

Unequal distribution of COVID-19 risk among rural residents by race and ethnicity

Risk for COVID-19 Infection, Hospitalization

Clinical Management of Confirmed COVID-19 Case in Adult and Paediatric

A prospective, multi-centre, observational study to determine the incidence and outcome of acute kidney injury among hospitalized patients in Malaysia

COVID-19 case-fatality rate and demographic and socioeconomic influencers: worldwide spatial regression analysis based on country-level data

Acute kidney injury in 3182 patients admitted with COVID-19: a single center retrospective case-control study

Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak

COVID-19 in grade 4-5 chronic kidney disease patients

Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, northern Italy

Acute kidney injury in SARS-CoV-2 infected patients

COVID-19 and acute kidney injury

Chronic kidney disease is a key risk factor for severe COVID-19: a call for action by ERA-EDTA

Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy

Risk factors for severity and mortality in adult COVID-19 patients in Wuhan

A geroscience perspective on COVID-19 mortality

The cytokine profiles and immune response are increased in COVID-19 patients with type 2 diabetes mellitus

Ethnicity and COVID-19: an urgent public health research priority

Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis. E

Outcomes of COVID-19: disparities by ethnicity

Bozok Cetintas V. Genetic and epigenetic factors associated with increased severity of Covid-19

Return to education by ethnicity: a case of Malaysia

Risk factors, clinical characteristics, and prognosis of acute kidney injury in hospitalized COVID-19 patients: a retrospective cohort study

Acute kidney injury in COVID-19: identification of risk factors and potential biomarkers of disease in a large UKcohort

Incidence, risk factors and outcome of acute kidney injury (AKI) in patients with COVID-19

Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO)

Pulmonary hypertension, mortality, and cardiovascular disease in CKD and ESRD patients: a systematic review and meta-analysis

Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Inter Urol and Nephrol

Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: a nationwide observational study

Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey

Size matters: a meta-analysis on the impact of hospital size on patient mortality